Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
Coya Therapeutics, Inc. (Name of Issuer) |
Common Stock, $0.0001 par value per share (Title of Class of Securities) |
22407B108 (CUSIP Number) |
01/30/2026 (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
 Rule 13d-1(b)
|
 Rule 13d-1(c)
|
| Rule 13d-1(d)
|
SCHEDULE 13G
|
| CUSIP No. | 22407B108 |
| 1 | Names of Reporting Persons
Dr. Reddy's Laboratories, Inc. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
NEW JERSEY
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,272,727.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
9.7 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
CO |
Comment for Type of Reporting Person: Note to Row 11: Based upon 20,924,456 shares of Common Stock of the Issuer outstanding as of November 10, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q ("Form 10-Q") filed with the Securities and Exchange Commission (the "SEC") on November 12, 2025 and 2,522,727 shares of Common Stock of the Issuer issued and outstanding as of January 29, 2026, as reported in the Issuer's Form 8-K filed with the SEC on January 30, 2026.
SCHEDULE 13G
|
| CUSIP No. | 22407B108 |
| 1 | Names of Reporting Persons
Dr. Reddy's Laboratories SA | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
SWITZERLAND
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 |
Aggregate Amount Beneficially Owned by Each Reporting Person
2,272,727.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
9.7 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person: Note to Rows 5, 7 and 9: Represents shares directly held by Dr. Reddy's Laboratories, Inc., a wholly-owned subsidiary of Dr. Reddy's Laboratories SA. Dr. Reddy's Laboratories SA is a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited. As a result, each of Dr. Reddy's Laboratories Limited and Dr. Reddy's Laboratories SA may each be deemed to beneficially own the shares held by Dr. Reddy's Laboratories Inc. Note to Row 11: Based upon 20,924,456 shares of Common Stock of the Issuer outstanding as of November 10, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025 and 2,522,727 shares of Common Stock of the Issuer issued and outstanding as of January 29, 2026, as reported in the Issuer's Form 8-K filed with the SEC on January 30, 2026.
SCHEDULE 13G
|
| CUSIP No. | 22407B108 |
| 1 | Names of Reporting Persons
Dr. Reddy's Laboratories Limited | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
INDIA
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,272,727.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
9.7 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person: Note to Rows 5, 7 and 9: Represents shares directly held by Dr. Reddy's Laboratories, Inc., a wholly-owned subsidiary of Dr. Reddy's Laboratories SA. Dr. Reddy's Laboratories SA is a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited. As a result, each of Dr. Reddy's Laboratories Limited and Dr. Reddy's Laboratories SA may each be deemed to beneficially own the shares held by Dr. Reddy's Laboratories Inc. Note to Row 11: Based upon 20,924,456 shares of Common Stock of the Issuer outstanding as of November 10, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025 and 2,522,727 shares of Common Stock of the Issuer issued and outstanding as of January 29, 2026, as reported in the Issuer's Form 8-K filed with the SEC on January 30, 2026.
SCHEDULE 13G
|
| Item 1. | ||
| (a) | Name of issuer:
Coya Therapeutics, Inc. | |
| (b) | Address of issuer's principal executive offices:
5850 San Felipe St., Suite 500, Houston, TX 77057 | |
| Item 2. | ||
| (a) | Name of person filing:
Dr. Reddy's Laboratories, Inc. Dr. Reddy's Laboratories SA Dr. Reddy's Laboratories Limited | |
| (b) | Address or principal business office or, if none, residence:
Dr. Reddy's Laboratories, Inc. - 600 College Road East, Suite 4000, Princeton, NJ 08540 Dr. Reddy's Laboratories SA - Grosspeter Tower Grosspeteranlage 294052 Basel, Switzerland Dr. Reddy's Laboratories Limited - 8-2-337, Road No. 3, Banjara Hills Hyderabad, Telangana 500 034, India | |
| (c) | Citizenship:
Dr. Reddy's Laboratories, Inc. - New Jersey Dr. Reddy's Laboratories SA - Switzerland Dr. Reddy's Laboratories Limited - Republic of India | |
| (d) | Title of class of securities:
Common Stock, $0.0001 par value per share | |
| (e) | CUSIP No.:
22407B108 | |
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
| (a) | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
| |
| (b) | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
| |
| (c) | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
| |
| (d) | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
| |
| (e) | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
| |
| (f) | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
| |
| (g) | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
| |
| (h) | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
| |
| (i) | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
| |
| (j) | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution: | |
| (k) | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
| |
| Item 4. | Ownership | |
| (a) | Amount beneficially owned:
Dr. Reddy's Laboratories, Inc. is the record owner of 2,272,727 shares of Common Stock of the Issuer. Dr. Reddy's Laboratories, Inc. is a wholly-owned subsidiary of Dr. Reddy's Laboratories SA and Dr. Reddy's Laboratories SA is a wholly-own subsidiary of Dr. Reddy's Laboratories Limited. Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories SA and Dr. Reddy's Laboratories, Inc. may be deemed to beneficially own these securities. | |
| (b) | Percent of class:
9.7% %
| |
| (c) | Number of shares as to which the person has:
| |
| (i) Sole power to vote or to direct the vote:
Dr. Reddy's Laboratories, Inc. - 2,272,727 Dr. Reddy's Laboratories SA - 2,272,727 Dr. Reddy's Laboratories Limited - 2,272,727 | ||
| (ii) Shared power to vote or to direct the vote:
Dr. Reddy's Laboratories, Inc. - None Dr. Reddy's Laboratories SA - None Dr. Reddy's Laboratories Limited - None | ||
| (iii) Sole power to dispose or to direct the disposition of:
Dr. Reddy's Laboratories, Inc. - 2,272,727 Dr. Reddy's Laboratories SA - 2,272,727 Dr. Reddy's Laboratories Limited - 2,272,727 | ||
| (iv) Shared power to dispose or to direct the disposition of:
Dr. Reddy's Laboratories, Inc. - None Dr. Reddy's Laboratories SA - None Dr. Reddy's Laboratories Limited - None | ||
| Item 5. | Ownership of 5 Percent or Less of a Class. | |
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
| Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
| Item 9. | Notice of Dissolution of Group. | |
Not Applicable
| ||
| Item 10. | Certifications: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|